X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (5455) 5455
Publication (671) 671
Book Review (125) 125
Book Chapter (91) 91
Book / eBook (11) 11
Conference Proceeding (7) 7
Dissertation (2) 2
Government Document (1) 1
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (4057) 4057
index medicus (3575) 3575
oncology (2760) 2760
cancer (2123) 2123
female (1882) 1882
male (1585) 1585
chemotherapy (1488) 1488
middle aged (1401) 1401
aged (1294) 1294
adult (1132) 1132
animals (1086) 1086
care and treatment (1014) 1014
advanced solid tumors (902) 902
pharmacology & pharmacy (867) 867
treatment outcome (866) 866
advanced basic science (835) 835
tumors (730) 730
medicine & public health (723) 723
antineoplastic agents - therapeutic use (714) 714
neoplasms - drug therapy (684) 684
antineoplastic combined chemotherapy protocols - therapeutic use (683) 683
research (675) 675
analysis (608) 608
metastasis (605) 605
hematology (602) 602
health aspects (575) 575
hematology, oncology and palliative medicine (542) 542
prognosis (524) 524
clinical trials (515) 515
phase-ii trial (497) 497
aged, 80 and over (492) 492
cell lung-cancer (491) 491
immunotherapy (490) 490
therapy (465) 465
article (453) 453
survival (449) 449
medicine, research & experimental (410) 410
drug therapy (408) 408
cancer therapies (403) 403
surgery (391) 391
cisplatin (390) 390
phase-i (388) 388
carcinoma (382) 382
antineoplastic agents (379) 379
mice (377) 377
radiotherapy (376) 376
neoplasm staging (375) 375
cell biology (362) 362
patients (362) 362
antineoplastic combined chemotherapy protocols - adverse effects (354) 354
cell line, tumor (354) 354
antimitotic agents (353) 353
clinical trials as topic (353) 353
cancer research (347) 347
disease-free survival (346) 346
antineoplastic agents - pharmacology (330) 330
apoptosis (323) 323
advanced cancer (319) 319
breast-cancer (318) 318
advanced breast-cancer (314) 314
pharmacology/toxicology (310) 310
antineoplastic agents - administration & dosage (296) 296
antineoplastic agents - adverse effects (292) 292
trial (286) 286
angiogenesis (283) 283
dentistry (282) 282
solid tumors (282) 282
open-label (277) 277
medical research (276) 276
combined modality therapy (275) 275
retrospective studies (275) 275
advanced melanoma (274) 274
survival rate (272) 272
review (271) 271
development and progression (269) 269
squamous-cell carcinoma (269) 269
expression (268) 268
survival analysis (268) 268
breast cancer (263) 263
neoplasms - pathology (263) 263
phase-ii (255) 255
toxicity (254) 254
oncology, experimental (252) 252
biotechnology & applied microbiology (247) 247
endothelial growth-factor (246) 246
double-blind (244) 244
engineering, biomedical (243) 243
medical prognosis (243) 243
materials science, biomaterials (242) 242
paclitaxel (239) 239
dose-response relationship, drug (237) 237
gemcitabine (237) 237
deoxycytidine - analogs & derivatives (234) 234
phase-i trial (232) 232
drug administration schedule (227) 227
pharmacokinetics (227) 227
biochemistry & molecular biology (225) 225
medical colleges (225) 225
studies (225) 225
antitumor-activity (222) 222
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (8) 8
Collection Dvlpm't (Acquisitions) - Closed Orders (2) 2
Providence Healthcare - Stacks (2) 2
Toronto East General Hospital - Stacks (2) 2
Humber River Regional Hospital - Church Stacks (1) 1
St. Michael's Hospital - Stacks (1) 1
Trinity College (John W Graham) - Stacks (1) 1
West Park Healthcare Centre - Stacks (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Oncologist, ISSN 1083-7159, 01/2017, Volume 22, Issue 1, pp. 53 - 60
Introduction There are increasing concerns about the negative impacts of chemotherapy near the end of life (EOL). There is discrepancy among different... 
Advanced solid cancer | End‐of‐life | Palliative chemotherapy | End-of-life | SURVIVAL | SYSTEM | EARLY PALLIATIVE CARE | TRENDS | CELL LUNG-CANCER | ONCOLOGY | AGGRESSIVENESS | QUALITY-OF-LIFE | HEALTH-CARE | SINGLE-CENTER ANALYSIS | AGE | Global Health and Cancer
Journal Article
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 06/2008, Volume 14, Issue 11, pp. 3456 - 3461
Journal Article
OncoImmunology, ISSN 2162-4011, 10/2018, Volume 7, Issue 10, p. e1494113
Myeloid-derived suppressor cells (MDSCs) have been shown to contribute to tumor progression, mainly through immune suppression. Inverse correlations have been... 
meta-analysis | MDSCs | solid malignancies | prognosis | LUNG-CANCER PATIENTS | ADVANCED MELANOMA PATIENTS | HEPATOCELLULAR-CARCINOMA PATIENTS | IMMUNOLOGY | MYELOID CELLS | ONCOLOGY | IMMUNE SUPPRESSION | POOR-PROGNOSIS | REGULATORY T-CELLS | SUPPRESSOR-CELLS CORRELATE | TUMOR MICROENVIRONMENT | CLINICAL-SIGNIFICANCE
Journal Article
Annals of Oncology, ISSN 0923-7534, 05/2012, Volume 23, Issue 5, pp. 1307 - 1313
Journal Article
JOURNAL FOR IMMUNOTHERAPY OF CANCER, ISSN 2051-1426, 08/2019, Volume 7, Issue 1, pp. 225 - 15
Background The safety, efficacy, pharmacokinetics, and pharmacodynamics of the anti-programmed cell death-1 antibody MEDI0680 were evaluated in a phase I,... 
SAFETY | IFN-GAMMA | Melanoma | PERIPHERAL-BLOOD | IMMUNOLOGY | LUNG-CANCER | PEMBROLIZUMAB | ONCOLOGY | IMMUNE CHECKPOINT BLOCKADE | ADVANCED MELANOMA | MEDI0680 | Immunotherapy | Kidney cancer | NIVOLUMAB | PD-1 | T-CELLS | Gene expression
Journal Article
Investigational New Drugs, ISSN 0167-6997, 10/2013, Volume 31, Issue 5, pp. 1251 - 1256
Purpose To determine the maximum tolerated dose (MTD) and characterize the dose-limiting toxicities (DLT) of tanespimycin when given in combination with... 
Phase I Trials | Tanespimycin | Bortezomib | Medicine & Public Health | Oncology | Solid tumors | Pharmacology/Toxicology | ADULT PATIENTS | PROTEASOME INHIBITION | BREAST-CANCER | TRIAL | METASTATIC MELANOMA | DOSE-ESCALATION | LUNG-CANCER | ONCOLOGY | GELDANAMYCIN | 17-ALLYLAMINO-17-DEMETHOXYGELDANAMYCIN | PHARMACOLOGY & PHARMACY | REFRACTORY ADVANCED CANCERS | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Benzoquinones - administration & dosage | Humans | Middle Aged | Pyrazines - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Boronic Acids - adverse effects | Male | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Dose-Response Relationship, Drug | Antineoplastic Agents - adverse effects | Aged, 80 and over | Female | Lactams, Macrocyclic - administration & dosage | Boronic Acids - administration & dosage | Lactams, Macrocyclic - adverse effects | Treatment Outcome | Neoplasms - drug therapy | Protein Kinase Inhibitors - administration & dosage | Maximum Tolerated Dose | Pyrazines - adverse effects | Aged | Benzoquinones - adverse effects | Complications and side effects | Dosage and administration | Research | Drug therapy | Tumors | Studies | Drug dosages | Analysis | Pharmaceutical sciences | Index Medicus | bortezomib | solid tumors | tanespimycin
Journal Article
16.